As biopharma pipelines expand and development timelines compress, traditional outsourcing models are falling short. While they may add capacity, they rarely deliver
the agility, integration, or foresight needed to manage today’s global trial complexity.
With CDMO and NewAmsterdam Pharma working as one team, they designed a strategy that enabled them to: